Dupixent Attorneys
Many who turned to Dupixent (dupilumab)—an injection used to treat eczema and other inflammatory skin conditions—are now questioning its safety. However, reports have surfaced that the drug masked symptoms of a rare cancer called cutaneous T-cell lymphoma (CTCL), delaying diagnosis. For many, that news has shaken their faith in a treatment they once trusted. Lawsuits have since followed, claiming that the makers of Dupixent, Regeneron Pharmaceuticals and Sanofi, didn’t do enough to warn patients and doctors about the risks.
FREE CASE REVIEW
Dupixent, also known as dupilumab, is a prescription injection developed to calm inflammation in the skin and airways. For many, it’s been a breakthrough that brought relief after they spent years struggling with eczema or other conditions. But some patients say they developed serious side effects, including a rare cancer called cutaneous T-cell lymphoma. If you took Dupixent and were later diagnosed with this condition, you may have the right to take legal action.
What Is Dupixent?
Dupixent is what’s known as a monoclonal antibody, which is a lab-made protein that targets specific pathways in your immune system. It works by blocking two key signals, IL-4 and IL-13, which trigger certain types of inflammation that lead to symptoms like rashes, itching, and airway swelling. The U.S. Food and Drug Administration first approved Dupixent in 2017, and since then, its label has been updated several times as new uses and safety information have come to light.
How Dupixent Is Administered
Dupixent is typically injected under the skin. After receiving training, patients use a prefilled syringe or an autoinjector at home to take the medication. Some people receive the first dose in a doctor’s office so a nurse can demonstrate the steps and watch for side effects. Injections are given on a regular schedule set by the prescriber, and patients are taught to rotate injection sites such as the thigh or abdomen to reduce irritation.
Who Makes and Markets Dupixent
Dupixent is manufactured by Regeneron Pharmaceuticals, Inc., and is marketed in the United States by Sanofi-Aventis U.S. LLC, together with Regeneron. These companies co-developed the medicine and continue to support research, safety monitoring, and education for patients and clinicians.
Regeneron Pharmaceuticals
Regeneron is a U.S.-based biotechnology company known for developing antibody medicines. Its scientists helped design dupilumab and moved it through clinical studies in several inflammatory diseases. Regeneron conducts research, manufacturing, and quality operations in the United States and works with doctors and hospitals to explore new uses and monitor real-world safety.
Sanofi and Sanofi-Aventis U.S. LLC
Sanofi is a global healthcare company with research and commercial teams around the world. Its U.S. affiliate, Sanofi-Aventis U.S. LLC, helps bring Dupixent to market in the United States and supports medical information, drug-safety monitoring, and patient access programs. Sanofi continues to collaborate with Regeneron on new studies and on clear communication to doctors and patients as approvals and guidance evolve.
$2+ BILLION IN RESULTS
What Does Dupixent Treat?
Dupixent’s approved uses have grown over time. Doctors now prescribe it for adults and children with atopic dermatitis. It is also used as an add-on medicine for certain types of asthma. People with chronic rhinosinusitis and nasal polyps may qualify, too. In recent years, the FDA added eosinophilic esophagitis and prurigo nodularis to the list of conditions treatable by Dupixent. Some patients with chronic obstructive pulmonary disease with an eosinophilic pattern now receive Dupixent as well. As science moves forward, the label may continue to evolve. Doctors also sometimes treat conditions that are not listed on the label when there is evidence and judgment to support it.
What Is Eczema?
Eczema, also known as atopic dermatitis, is a chronic skin condition that causes the skin to become dry, itchy, and inflamed. It often appears as red, scaly patches that can crack or ooze, and the itching can be intense enough to disrupt sleep or daily life. While eczema can affect anyone, it often begins in childhood and may come and go over time. Eczema occurs when the skin’s natural barrier doesn’t work as well as it should, allowing irritants and allergens to trigger an overactive immune response.
There’s no single cause of eczema—it can be influenced by genetics, environmental triggers, stress, and even certain foods or chemicals. Treatments like moisturizers, topical creams, and newer biologic medications such as Dupixent are often prescribed to help manage symptoms and reduce flare-ups.
Side Effects of Taking Dupixent
Most people tolerate Dupixent well, but side effects can happen. Injection-site reactions are common. Redness, swelling, or tenderness can appear for a few days. Many patients also report eye irritation. Conjunctivitis (inflammation of the inner eyelid) and keratitis (inflammation of the cornea) are common issues that require prompt attention if vision changes, light sensitivity, or eye pain develop.
Additionally, patients may experience hypersensitivity reactions. Hives, swelling, or trouble breathing require immediate medical attention. Doctors also want to know about joint pain or new rashes. Recently, new-onset psoriasis, psoriatic arthritis, and forms of vasculitis have been noted.
Dupixent’s Connection to CTCL
Cutaneous T-cell lymphoma, or CTCL, is a rare cancer of immune cells that often starts with skin changes that can look like stubborn eczema. Because the early signs can mimic common rashes, doctors urge patients on Dupixent to report plaques or patches that stop behaving as expected so the care team can decide whether a biopsy is needed to rule out lymphoma or confirm the diagnosis.
Over the past few years, dermatology researchers have noticed an increase in patients who used dupilumab for difficult dermatitis and were later diagnosed with CTCL. Although some defenders of dupilumab argue that CTCL may have already been present in these patients, the medical community has moved to maintain a low threshold for biopsy when rashes do not follow the usual pattern.
What Is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that starts in the body’s T-cells, a part of the immune system that helps fight infections. In CTCL, these cells grow out of control and collect in the skin, leading to patches, plaques, or tumors that can look a lot like eczema or psoriasis. Because of that, CTCL is sometimes difficult to recognize at first—and may even be mistaken for another skin condition.
CTCL has several subtypes, including Mycosis Fungoides and Sézary Syndrome, which are the most common.
- Mycosis Fungoides
- Sézary Syndrome
- Lymphomatoid Papulosis
- Subcutaneous
- Panniculitis-like T-Cell Lymphoma
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Extranodal NK/T-Cell Lymphoma
- Primary Cutaneous Gamma/Delta T-Cell Lymphoma
Symptoms can include red or scaly skin, itching, thickened patches, or enlarged lymph nodes. In more advanced stages, the cancer can spread to the blood, lymph nodes, or internal organs.
When To Check With Your Doctor
Pay attention to rashes that change shape or color. Take note of patches that thicken, crack, or bleed. Report night sweats, unexplained fevers, or swollen lymph nodes. These symptoms do not prove cancer. They are signals to check in with your doctor and make a plan. A careful exam and a biopsy when needed can separate persistent eczema from lymphoma. Early testing protects your health and creates a clear medical record that explains what happened and when.
A simple health journal can be powerful. Write down dates of injections, new symptoms, and any office visits. Photos of rashes taken a few weeks apart can show changes your memory might miss. This record helps your doctor adjust treatment. It also helps a legal team understand your story if you pursue a claim later.
What the FDA Says About Dupixent
The U.S. Food and Drug Administration continues to review safety data for approved medicines, including Dupixent, and recent label updates have focused on known issues such as eye disorders and other immune-related events. Public reporting indicates the agency has been evaluating CTCL reports and whether additional warning language is appropriate.
Has Dupixent Been Recalled?
There are currently no FDA-announced drug recalls for Dupixent. People sometimes see alarming posts online about recalls. Many of those posts mix up drug recalls with device reports or notices in other countries. If you have Dupixent boxes at home and want to check the lot number, your pharmacy can assist you. Your doctor can also confirm the status when you bring the package to your next appointment.
Autoinjectors are medical devices. They can have their own reports that do not involve a recall of the drug itself. A device report may lead to a fix in how the injector is made or packaged. It does not always mean the medicine is being pulled from shelves.
Dupixent Lawsuits
Across the country, patients have begun filing lawsuits that focus on lymphoma diagnoses that followed Dupixent use. The main claim is failure to warn. Plaintiffs argue the warnings and guidance provided by the manufacturers were not strong enough to protect patients and doctors. These filings seek accountability for injuries and losses tied to late recognition of lymphoma.
A Wrongful Death Dupixent Lawsuit in Tennessee
On October 1, 2025, a wrongful-death lawsuit has been filed listing Regeneron and Sanofi-Aventis U.S. LLC by the daughter of Cynthia Hyde, Chandra Richardson. Ms.Hyde died from lymphoma after beginning use of Dupixent. The complaint alleges that Ms. Richardon’s mother developed a T-cell lymphoma after receiving Dupixent and that the manufacturers failed to provide adequate warnings about the risk of lymphoma or about the potential for the drug to mask early signs of disease and delay diagnosis. The filing asserts product-liability theories including failure to warn and negligence, as well as wrongful death and related claims.
According to reporting on the complaint, Cynthia Marie Hyde was treated for adult-onset atopic dermatitis in 2019, and was prescribed Dupixent in May 2024. She received injections of Dupixent in June and July 2024. After the injections, her skin condition reportedly worsened, with raised scars and widespread darkened, swollen patches. In September 2024, a biopsy indicated peripheral T-cell lymphoma (PTCL), and she died on October 28, 2024. The lawsuit contends Dupixent triggered or accelerated an underlying T-cell lymphoma process that led to her rapid decline.
The complaint brought against Regeneron and Sanofi-Aventis pleads failure to warn, negligence, negligent misrepresentation, breach of warranty, wrongful death, and survival causes of action. Richardson and her legal team are seeking damages tied to medical losses and the death of her mother, Cynthia Hyde. As this filing is relatively new, Regeneron and Sanofi-Aventis have not admitted liability, and no court has ruled on the merits at this stage.
Are There Dupixent MDL Lawsuits?
The Tennessee case, is among the first patient injury suits specifically tying Dupixent to T-cell lymphoma in a wrongful-death context. However, there are additional reports of CTCL-related Dupixent claims being investigated and filed nationwide. At this time, a multidistrict litigation has not been filed.
Do I Have a Dupixent Case?
If you used Dupixent for at least one month and later received a diagnosis of cutaneous T-cell lymphoma (CTCL) or a related subtype after your first dose, you may qualify for a claim. These subtypes include Mycosis Fungoides, Sézary Syndrome, Lymphomatoid Papulosis, Subcutaneous Panniculitis-like T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Extranodal NK/T-Cell Lymphoma, or Primary Cutaneous Gamma/Delta T-Cell Lymphoma.
Farah & Farah’s legal team is highly experienced with defective drug lawsuits and can help you fight the company that allowed a drug that had a risk of cancer to stay on the market. Don’t wait to get the justice and compensation you deserve. Contact Farah & Farah today for a free consultation. You pay nothing unless your case is successful.
FREE CASE REVIEW